A little bit of background news on our supplier Lonza.
Today Lonza announced a new CEO, effective 1 November 2020
The incoming CEO is Pierre-Alain Ruffieux. Below are some cherry picked quotes to illustrate where Lonza fits in with other BioPharma with bold for emphasis.
"Pierre-Alain is currently Head of Global Pharma Technical Operations at Roche where he and his 12,000-strong team are responsible for all aspects of pharmaceutical commercial manufacturing and supply chain operations, technical, quality assurance and regulatory. Prior to that he held roles of increasing seniority at Novartis and has over 20 years’ experience in biopharmaceuticals."
"Pierre-Alain Ruffieux, incoming Chief Executive Officer added: “I am delighted to have been appointed as CEO of Lonza. Having been a customer over many years, I greatly admire Lonza’s technology and people. I look forward to building on its many successes in the years to come.”"
"About Lonza
...
We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets."
The above selected quotes are from;
http://e3.marco.ch/publish/lonza/551_1215/20200604_Press_Release_CEO_Appointment_FINAL.pdf
Cell Therapy News/Articles, page-3197
-
- There are more pages in this discussion • 14,830 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
-0.015(1.55%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 96.5¢ | 96.5¢ | 94.5¢ | $2.433M | 2.552M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 72431 | 94.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 20225 | 5 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |